Tags

Type your tag names separated by a space and hit enter

[Antiangiogenic therapy in the surgical treatment of pterygium].
Vestn Oftalmol. 2020; 136(5. Vyp. 2):177-183.VO

Abstract

PURPOSE

To evaluate the effectiveness and safety of adjuvant anti-VEGF therapy in the surgical treatment of pterygium, and to determine the indications for its use.

MATERIAL AND METHODS

The study included 67 patients (69 eyes) with grade II-IV pterygium. Patients age was 58.8±12.6 years on average. Best corrected visual acuity (BCVA) varied between 0.01 and 1.0 (0.77±0.24). The patients were divided into 3 groups. The first group included 19 patients (19 eyes) with grade II-III pterygium who underwent «bare sclera» surgery and used aflibercept as adjuvant therapy. The second group included 21 patients (21 eyes) with grade II-IV pterygium who underwent auto conjunctival grafting surgery with no adjuvant therapy. The third group included 27 patients (29 eyes) with grade II-IV pterygium who had it removed in combination with single-time peripheral lamellar keratoplasty (PLK) and underwent adjuvant aflibercept therapy.

RESULTS

Among patients who underwent pterygium excision with adjuvant antiangiogenic therapy there were 5 cases (26%) of relapse during the observation period (23.38±8.96 months), among patients after pterygium excision with auto conjunctival plastic surgery - also 5 cases (24%) of relapse, and among patients who underwent LKP combined with anti-VEGF therapy there was only 1 case (3%) of relapse. Astigmatism has decreased by 0.24±0.5 (p=0.052) in the first group, by 1.21±1.0 (p<0.05) in the second group, and by 1.64±1.54 (p<0.05) in the third group compared with pre-surgical values, thus increasing average BCVA in all 3 patient groups by 0.1±0.13, 0.07±0.11 and 0.15±0.15, respectively.

CONCLUSION

The use of anti-VEGF agents as adjuvant therapy in the surgical treatment of pterygium is a safe method of reducing postoperative inflammation, fibrovascular proliferation and, subsequently, the amount of relapses.

Authors+Show Affiliations

Research Institute of Eye Diseases, Moscow, Russia.Research Institute of Eye Diseases, Moscow, Russia.Research Institute of Eye Diseases, Moscow, Russia.

Pub Type(s)

Journal Article

Language

rus

PubMed ID

33063961

Citation

Malozhen, S A., et al. "[Antiangiogenic Therapy in the Surgical Treatment of Pterygium]." Vestnik Oftalmologii, vol. 136, no. 5. Vyp. 2, 2020, pp. 177-183.
Malozhen SA, Trufanov SV, Krakhmaleva DA. [Antiangiogenic therapy in the surgical treatment of pterygium]. Vestn Oftalmol. 2020;136(5. Vyp. 2):177-183.
Malozhen, S. A., Trufanov, S. V., & Krakhmaleva, D. A. (2020). [Antiangiogenic therapy in the surgical treatment of pterygium]. Vestnik Oftalmologii, 136(5. Vyp. 2), 177-183. https://doi.org/10.17116/oftalma2020136052177
Malozhen SA, Trufanov SV, Krakhmaleva DA. [Antiangiogenic Therapy in the Surgical Treatment of Pterygium]. Vestn Oftalmol. 2020;136(5. Vyp. 2):177-183. PubMed PMID: 33063961.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Antiangiogenic therapy in the surgical treatment of pterygium]. AU - Malozhen,S A, AU - Trufanov,S V, AU - Krakhmaleva,D A, PY - 2020/10/16/entrez PY - 2020/10/17/pubmed PY - 2020/10/21/medline KW - aflibercept KW - anti-VEGF KW - auto conjunctival plastic surgery KW - peripheral lamellar keratoplasty KW - pterygium SP - 177 EP - 183 JF - Vestnik oftalmologii JO - Vestn Oftalmol VL - 136 IS - 5. Vyp. 2 N2 - PURPOSE: To evaluate the effectiveness and safety of adjuvant anti-VEGF therapy in the surgical treatment of pterygium, and to determine the indications for its use. MATERIAL AND METHODS: The study included 67 patients (69 eyes) with grade II-IV pterygium. Patients age was 58.8±12.6 years on average. Best corrected visual acuity (BCVA) varied between 0.01 and 1.0 (0.77±0.24). The patients were divided into 3 groups. The first group included 19 patients (19 eyes) with grade II-III pterygium who underwent «bare sclera» surgery and used aflibercept as adjuvant therapy. The second group included 21 patients (21 eyes) with grade II-IV pterygium who underwent auto conjunctival grafting surgery with no adjuvant therapy. The third group included 27 patients (29 eyes) with grade II-IV pterygium who had it removed in combination with single-time peripheral lamellar keratoplasty (PLK) and underwent adjuvant aflibercept therapy. RESULTS: Among patients who underwent pterygium excision with adjuvant antiangiogenic therapy there were 5 cases (26%) of relapse during the observation period (23.38±8.96 months), among patients after pterygium excision with auto conjunctival plastic surgery - also 5 cases (24%) of relapse, and among patients who underwent LKP combined with anti-VEGF therapy there was only 1 case (3%) of relapse. Astigmatism has decreased by 0.24±0.5 (p=0.052) in the first group, by 1.21±1.0 (p<0.05) in the second group, and by 1.64±1.54 (p<0.05) in the third group compared with pre-surgical values, thus increasing average BCVA in all 3 patient groups by 0.1±0.13, 0.07±0.11 and 0.15±0.15, respectively. CONCLUSION: The use of anti-VEGF agents as adjuvant therapy in the surgical treatment of pterygium is a safe method of reducing postoperative inflammation, fibrovascular proliferation and, subsequently, the amount of relapses. SN - 0042-465X UR - https://www.unboundmedicine.com/medline/citation/33063961/[Antiangiogenic_therapy_in_the_surgical_treatment_of_pterygium]_ L2 - https://medlineplus.gov/cornealdisorders.html DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.